Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition

  • Rodríguez Martín, Bernardo
  • PCAWG Structural Variation Working Group
  • PCAWG Consortium
  • Ossowski, Stephan
About half of all cancers have somatic integrations of retrotransposons. Here, to characterize their role in oncogenesis, we analyzed the patterns and mechanisms of somatic retrotransposition in 2,954 cancer genomes from 38 histological cancer subtypes within the framework of the Pan-Cancer Analysis of Whole Genomes (PCAWG) project. We identified 19,166 somatically acquired retrotransposition events, which affected 35% of samples and spanned a range of event types. Long interspersed nuclear element (LINE-1; L1 hereafter) insertions emerged as the first most frequent type of somatic structural variation in esophageal adenocarcinoma, and the second most frequent in head-and-neck and colorectal cancers. Aberrant L1 integrations can delete megabase-scale regions of a chromosome, which sometimes leads to the removal of tumor-suppressor genes, and can induce complex translocations and large-scale duplications. Somatic retrotranspositions can also initiate breakage-fusion-bridge cycles, leading to high-level amplification of oncogenes. These observations illuminate a relevant role of L1 retrotransposition in remodeling the cancer genome, with potential implications for the development of human tumors., J.M.C.T. is supported by European Research Council (ERC) Starting Grant 716290 ‘SCUBA CANCERS’, Ramon y Cajal grant RYC-2014-14999 and Spanish Ministry of Economy, Industry and Competitiveness (MINECO) grant SAF2015-66368-P. B.R.-M., E.G.A., M.S.G. and S.Z. are supported by PhD fellowships from Xunta de Galicia (Spain) ED481A-2016/151, ED481A-2017/299, ED481A-2017/306 and ED481A-2018/199, respectively. F.S. was supported by ERC Starting Grant 757700 ‘HYPER-INSIGHT’, MINECO grant BFU2017-89833-P ‘RegioMut’, and further acknowledges institutional funding from the MINECO Severo Ochoa award and from the CERCA Programme of the Catalan Government. Y.S.J. was supported by Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI16C2387). A.L.B. is supported by MINECO PhD fellowship BES-2016-078166. M.T. was supported by MINECO grant SAF2015-73916-JIN. R.B. received funding through the National Institutes of Health (U24CA210978 and R01CA188228). M.G.B. received funding through MINECO, AEI, Xunta de Galicia and FEDER (BFU2013-41554-P, BFU2016-78121-P, ED431F 2016/019). N.B. is supported by a My First AIRC grant from the Associazione Italiana Ricerca sul Cancro (number 17658). J.D. is a postdoctoral fellow of the Research Foundation Flanders (FWO) and the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant agreement number 703594-DECODE). K.C. and Z.C. are supported by NIH R01 CA172652 and U41 HG007497. Z.C. is supported by an American Heart Association Institutional Data Fellowship Award (17IF33890015). P.A.W.E. is supported by Cancer Research UK. E.A.L. is supported by K01AG051791. I.M. is supported by Cancer Research UK (C57387/A21777). S.M.W. received funding through a SNSF Early Postdoc Mobility fellowship (P2ELP3_155365) and an EMBO Long-Term Fellowship (ALTF 755-2014). J.W. received funding from the Danish Medical Research Council (DFF-4183-00233). J.O.K. is supported by an ERC Starting Grant. This work is supported by The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001202), the UK Medical Research Council (FC001202) and the Wellcome Trust (FC001202). H.H.K. is supported by grants from the National Institute of General Medical Sciences (P50GM107632 and 1R01GM099875). K.H.B. is supported by P50GM107632, R01CA163705 and R01GM124531. This work was supported by the TransTumVar project PN013600.. This work was supported by the Wellcome Trust grant 09805
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

To NMD or not to NMD: nonsense-mediated mRNA decay in cancer and other genetic diseases

  • Supek, Fran
  • Lehner, Ben, 1978-
  • Lindeboom, Rik G.H.
The nonsense-mediated mRNA decay (NMD) pathway degrades some but not all mRNAs bearing premature termination codons (PTCs). Decades of work have elucidated the molecular mechanisms of NMD. More recently, statistical analyses of large genomic datasets have allowed the importance of known and novel 'rules of NMD' to be tested and combined into methods that accurately predict whether PTC-containing mRNAs are degraded or not. We discuss these genomic approaches and how they can be applied to identify diseases and individuals that may benefit from inhibition or activation of NMD. We also discuss the importance of NMD for gene editing and tumor evolution, and how inhibiting NMD may be an effective strategy to increase the efficacy of cancer immunotherapy., This work was funded by the European Research Council (ERC) starting grant HYPER-INSIGHT ( 757700 , to F.S.) and ERC consolidator grant IR-DC ( 616434 to B.L.). F.S. and B.L. are funded by the ICREA Research Professor program. F.S. and B.L. acknowledge support of the Severo Ochoa Centres of Excellence program to the IRB Barcelona and to the CRG, respectively. B.L. and F.S. were supported by the Fondo Europeo de Desarrollo Regional (FEDER)/ Ministerio de Ciencia, Innovación y Universidades - Agencia Estatal de Investigación projects BFU2017-89488-P and RegioMut ( BFU2017-89833-P ), respectively. B.L. was further supported by the Bettencourt Schueller Foundation , the Agencia de Gestio d'Ajuts Universitaris i de Recerca ( 2017 SGR 1322 ), and the Centres de Recerca de Catalunya (CERCA) program/ Generalitat de Catalunya . B.L. also acknowledges the support of the Spanish Ministry of Economy, Industry, and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The impact of rare germline variants on human somatic mutation processes

  • Vali-Pour, Mischan
  • Solip, Park
  • Espinosa-Carrasco, José
  • Ortiz-Martínez, Daniel
  • Lehner, Ben, 1978-
  • Supek, Fran
Somatic mutations are an inevitable component of ageing and the most important cause of cancer. The rates and types of somatic mutation vary across individuals, but relatively few inherited influences on mutation processes are known. We perform a gene-based rare variant association study with diverse mutational processes, using human cancer genomes from over 11,000 individuals of European ancestry. By combining burden and variance tests, we identify 207 associations involving 15 somatic mutational phenotypes and 42 genes that replicated in an independent data set at a false discovery rate of 1%. We associate rare inherited deleterious variants in genes such as MSH3, EXO1, SETD2, and MTOR with two phenotypically different forms of DNA mismatch repair deficiency, and variants in genes such as EXO1, PAXIP1, RIF1, and WRN with deficiency in homologous recombination repair. In addition, we identify associations with other mutational processes, such as APEX1 with APOBEC-signature mutagenesis. Many of the genes interact with each other and with known mutator genes within cellular sub-networks. Considered collectively, damaging variants in the identified genes are prevalent in the population. We suggest that rare germline variation in diverse genes commonly impacts mutational processes in somatic cells., M.V.P. was supported by a Spanish Ministry of Science and Innovation FPI Fellowship (ref.: PRE2018-084410). Work in the lab of B.L. is funded by European Research Council (ERC) Advanced (883742) and Consolidator (616434) grants, the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Centre of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322), and the CERCA Program/Generalitat de Catalunya. Work in the lab of F.S. is funded by the ERC Starting Grant HYPER-INSIGHT (757700), the Horizon2020 RIA grant DECIDER (965193), Spanish Ministry of Science and Innovation grant REPAIRSCAPE (PID2020-118795GB-I00), the EMBO YIP program, the Severo Ochoa Centre of Excellence award to IRB Barcelona, and the CERCA Program/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules

  • Toledano, Ignasi
  • Supek, Fran
  • Lehner, Ben
Premature termination codons (PTCs) cause ~10-20% of inherited diseases and are a major mechanism of tumor suppressor gene inactivation in cancer. A general strategy to alleviate the effects of PTCs would be to promote translational readthrough. Nonsense suppression by small molecules has proven effective in diverse disease models, but translation into the clinic is hampered by ineffective readthrough of many PTCs. Here we directly tackle the challenge of defining drug efficacy by quantifying the readthrough of ~5,800 human pathogenic stop codons by eight drugs. We find that different drugs promote the readthrough of complementary subsets of PTCs defined by local sequence context. This allows us to build interpretable models that accurately predict drug-induced readthrough genome-wide, and we validate these models by quantifying endogenous stop codon readthrough. Accurate readthrough quantification and prediction will empower clinical trial design and the development of personalized nonsense suppression therapies., Work in the Supek laboratory was supported by an ERC StG ‘HYPER-INSIGHT’ (757700) and ERC CoG ‘STRUCTOMATIC’ (101088342), Horizon2020 project ‘DECIDER’ (965193), Horizon Europe project ‘LUCIA’ (101096473), Spanish government project ‘REPAIRSCAPE’, CaixaResearch project ‘POTENT-IMMUNO’ (HR22-00402), an ICREA professorship to F.S., the SGR funding from the Catalan government and a Novo Nordisk Fonden starting package. Work in the Lehner laboratory was funded by European Research Council (ERC) Advanced (grant 883742) and Consolidator (grant 616434), the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Center of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322) and the CERCA Program/Generalitat de Catalunya. The authors would like to thank the four members E. Ramírez, A. Bote, E. Julià and Ò. Fornàs of the Flow Cytometry CRG Core Unit for their support and time, together with G. Palou (IRB) for his help in retrieving the transcript sequences from the Ensembl database and all members of the Supek and Lehner laboratories for helpful discussions and suggestions.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The impact of rare germline variants on human somatic mutation processes

  • Vali-Pour, Mischan
  • Lehner, Ben, 1978-
  • Supek, Fran
Somatic mutations are an inevitable component of ageing and the most important cause of cancer. The rates and types of somatic mutation vary across individuals, but relatively few inherited influences on mutation processes are known. We perform a gene-based rare variant association study with diverse mutational processes, using human cancer genomes from over 11,000 individuals of European ancestry. By combining burden and variance tests, we identify 207 associations involving 15 somatic mutational phenotypes and 42 genes that replicated in an independent data set at a false discovery rate of 1%. We associate rare inherited deleterious variants in genes such as MSH3, EXO1, SETD2, and MTOR with two phenotypically different forms of DNA mismatch repair deficiency, and variants in genes such as EXO1, PAXIP1, RIF1, and WRN with deficiency in homologous recombination repair. In addition, we identify associations with other mutational processes, such as APEX1 with APOBEC-signature mutagenesis. Many of the genes interact with each other and with known mutator genes within cellular sub-networks. Considered collectively, damaging variants in the identified genes are prevalent in the population. We suggest that rare germline variation in diverse genes commonly impacts mutational processes in somatic cells., M.V.P. was supported by a Spanish Ministry of Science and Innovation FPI Fellowship (ref.: PRE2018-084410). Work in the lab of B.L. is funded by European Research Council (ERC) Advanced (883742) and Consolidator (616434) grants, the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Centre of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322), and the CERCA Program/Generalitat de Catalunya. Work in the lab of F.S. is funded by the ERC Starting Grant HYPER-INSIGHT (757700), the Horizon2020 RIA grant DECIDER (965193), Spanish Ministry of Science and Innovation grant REPAIRSCAPE (PID2020-118795GB-I00), the EMBO YIP program, the Severo Ochoa Centre of Excellence award to IRB Barcelona, and the CERCA Program/Generalitat de Catalunya. We thank Solip Park for method consultations, comments, and discussions.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Higher order genetic interactions switch cancer genes from two-hit to one-hit drivers

  • Park, Solip
  • Supek, Fran
  • Lehner, Ben, 1978-
The classic two-hit model posits that both alleles of a tumor suppressor gene (TSG) must be inactivated to cause cancer. In contrast, for some oncogenes and haploinsufficient TSGs, a single genetic alteration can suffice to increase tumor fitness. Here, by quantifying the interactions between mutations and copy number alterations (CNAs) across 10,000 tumors, we show that many cancer genes actually switch between acting as one-hit or two-hit drivers. Third order genetic interactions identify the causes of some of these switches in dominance and dosage sensitivity as mutations in other genes in the same biological pathway. The correct genetic model for a gene thus depends on the other mutations in a genome, with a second hit in the same gene or an alteration in a different gene in the same pathway sometimes representing alternative evolutionary paths to cancer., This work was funded by the European Research Council (ERC) Starting grant (HYPER-INSIGHT, 757700) to F.S. and ERC Consolidator (IR-DC, 616434) and Advanced (MUTANOMICS, 883742) grants to B.L. F.S. and B.L. are funded by the ICREA Research Professor program. S.P., F.S., and B.L. acknowledge the support of the Severo Ochoa Centres of Excellence program to the CNIO, IRB Barcelona, and to the CRG (MCIN/AEI/10.13039/50110001103), respectively. B.L. and F.S. Work is funded with the grants BFU2017-89488-P and RegioMut BFU2017-89833-P (MCIN/AEI /10.13039/501100011033/FEDER “A way to make Europe”), respectively. B.L. is further supported by the Bettencourt Schueller Foundation, the Agencia de Gestio d’Ajuts Universitaris i de Recerca (2017 SGR 1322), and the Centres de Recerca de Catalunya (CERCA) program/Generalitat de Catalunya. B.L. also acknowledges the support of the Spanish Ministry of Economy, Industry, and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership. The results shown here are in whole or part based upon data generated by the TCGA Research Network.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Loss of G9a preserves mutation patterns but increases chromatin accessibility, genomic instability and aggressiveness in skin tumours

  • Avgustinova, Alexandra
  • Symeonidi, Aikaterini
  • Castellanos, Andrés
  • Urdiroz Urricelqui, Uxue
  • Solé Boldo, Llorenç
  • Martín, Mercè
  • Pérez Rodríguez, Ivan
  • Prats, Neus
  • Lehner, Ben, 1978-
  • Supek, Fran
  • Aznar Benitah, Salvador
Mutations in, and the altered expression of, epigenetic modifiers are pervasive in human tumours, making epigenetic factors attractive antitumour targets. The open-versus-closed chromatin state within the cells-of-origin of cancer correlates with the uneven distribution of mutations. However, the long-term effect of targeting epigenetic modifiers on mutability in patients with cancer is unclear. Here, we increased chromatin accessibility by deleting the histone H3 lysine 9 (H3K9) methyltransferase G9a in murine epidermis and show that this does not alter the single nucleotide variant burden or global genomic distribution in chemical mutagen-induced squamous tumours. G9a-depleted tumours develop after a prolonged latency compared with their wild-type counterparts, but are more aggressive and have an expanded cancer progenitor pool, pronounced genomic instability and frequent loss-of-function p53 mutations. Thus, we call for caution when assessing long-term therapeutic benefits of chromatin modifier inhibitors, which may promote more aggressive disease.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Scales and mechanisms of somatic mutation rate variation across the human genome

  • Supek, Fran
  • Lehner, Ben, 1978-
Cancer genome sequencing has revealed that somatic mutation rates vary substantially across the human genome and at scales from megabase-sized domains to individual nucleotides. Here we review recent work that has both revealed the major mutation biases that operate across the genome and the molecular mechanisms that cause them. The default mutation rate landscape in mammalian genomes results in active genes having low mutation rates because of a combination of factors that increase DNA repair: early DNA replication, transcription, active chromatin modifications and accessible chromatin. Therefore, either an increase in the global mutation rate or a redistribution of mutations from inactive to active DNA can increase the rate at which consequential mutations are acquired in active genes. Several environmental carcinogens and intrinsic mechanisms operating in tumor cells likely cause cancer by this second mechanism: by specifically increasing the mutation rate in active regions of the genome.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Higher order genetic interactions switch cancer genes from two-hit to one-hit drivers

  • Park, Solip
  • Supek, Fran
  • Lehner, Ben, 1978-
The classic two-hit model posits that both alleles of a tumor suppressor gene (TSG) must be inactivated to cause cancer. In contrast, for some oncogenes and haploinsufficient TSGs, a single genetic alteration can suffice to increase tumor fitness. Here, by quantifying the interactions between mutations and copy number alterations (CNAs) across 10,000 tumors, we show that many cancer genes actually switch between acting as one-hit or two-hit drivers. Third order genetic interactions identify the causes of some of these switches in dominance and dosage sensitivity as mutations in other genes in the same biological pathway. The correct genetic model for a gene thus depends on the other mutations in a genome, with a second hit in the same gene or an alteration in a different gene in the same pathway sometimes representing alternative evolutionary paths to cancer., This work was funded by the European Research Council (ERC) Starting grant (HYPER-INSIGHT, 757700) to F.S. and ERC Consolidator (IR-DC, 616434) and Advanced (MUTANOMICS, 883742) grants to B.L. F.S. and B.L. are funded by the ICREA Research Professor program. S.P., F.S., and B.L. acknowledge the support of the Severo Ochoa Centres of Excellence program to the CNIO, IRB Barcelona, and to the CRG (MCIN/AEI/10.13039/50110001103), respectively. B.L. and F.S. Work is funded with the grants BFU2017-89488-P and RegioMut BFU2017-89833-P (MCIN/AEI /10.13039/501100011033/FEDER “A way to make Europe”), respectively. B.L. is further supported by the Bettencourt Schueller Foundation, the Agencia de Gestio d’Ajuts Universitaris i de Recerca (2017 SGR 1322), and the Centres de Recerca de Catalunya (CERCA) program/Generalitat de Catalunya. B.L. also acknowledges the support of the Spanish Ministry of Economy, Industry, and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership. The results shown here are in whole or part based upon data generated by the TCGA Research Network.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Loss of G9a preserves mutation patterns but increases chromatin accessibility, genomic instability and aggressiveness in skin tumours

  • Avgustinova, Alexandra
  • Symeonidi, Aikaterini
  • Castellanos, Andrés
  • Urdiroz Urricelqui, Uxue
  • Solé Boldo, Llorenç
  • Martín, Mercè
  • Pérez Rodríguez, Ivan
  • Prats, Neus
  • Lehner, Ben, 1978-
  • Supek, Fran
  • Aznar Benitah, Salvador
Mutations in, and the altered expression of, epigenetic modifiers are pervasive in human tumours, making epigenetic factors attractive antitumour targets. The open-versus-closed chromatin state within the cells-of-origin of cancer correlates with the uneven distribution of mutations. However, the long-term effect of targeting epigenetic modifiers on mutability in patients with cancer is unclear. Here, we increased chromatin accessibility by deleting the histone H3 lysine 9 (H3K9) methyltransferase G9a in murine epidermis and show that this does not alter the single nucleotide variant burden or global genomic distribution in chemical mutagen-induced squamous tumours. G9a-depleted tumours develop after a prolonged latency compared with their wild-type counterparts, but are more aggressive and have an expanded cancer progenitor pool, pronounced genomic instability and frequent loss-of-function p53 mutations. Thus, we call for caution when assessing long-term therapeutic benefits of chromatin modifier inhibitors, which may promote more aggressive disease.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

To NMD or not to NMD: nonsense-mediated mRNA decay in cancer and other genetic diseases

  • Supek, Fran
  • Lehner, Ben, 1978-
  • Lindeboom, Rik G.H.
The nonsense-mediated mRNA decay (NMD) pathway degrades some but not all mRNAs bearing premature termination codons (PTCs). Decades of work have elucidated the molecular mechanisms of NMD. More recently, statistical analyses of large genomic datasets have allowed the importance of known and novel 'rules of NMD' to be tested and combined into methods that accurately predict whether PTC-containing mRNAs are degraded or not. We discuss these genomic approaches and how they can be applied to identify diseases and individuals that may benefit from inhibition or activation of NMD. We also discuss the importance of NMD for gene editing and tumor evolution, and how inhibiting NMD may be an effective strategy to increase the efficacy of cancer immunotherapy., This work was funded by the European Research Council (ERC) starting grant HYPER-INSIGHT ( 757700 , to F.S.) and ERC consolidator grant IR-DC ( 616434 to B.L.). F.S. and B.L. are funded by the ICREA Research Professor program. F.S. and B.L. acknowledge support of the Severo Ochoa Centres of Excellence program to the IRB Barcelona and to the CRG, respectively. B.L. and F.S. were supported by the Fondo Europeo de Desarrollo Regional (FEDER)/ Ministerio de Ciencia, Innovación y Universidades - Agencia Estatal de Investigación projects BFU2017-89488-P and RegioMut ( BFU2017-89833-P ), respectively. B.L. was further supported by the Bettencourt Schueller Foundation , the Agencia de Gestio d'Ajuts Universitaris i de Recerca ( 2017 SGR 1322 ), and the Centres de Recerca de Catalunya (CERCA) program/ Generalitat de Catalunya . B.L. also acknowledges the support of the Spanish Ministry of Economy, Industry, and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Scales and mechanisms of somatic mutation rate variation across the human genome

  • Supek, Fran
  • Lehner, Ben, 1978-
Cancer genome sequencing has revealed that somatic mutation rates vary substantially across the human genome and at scales from megabase-sized domains to individual nucleotides. Here we review recent work that has both revealed the major mutation biases that operate across the genome and the molecular mechanisms that cause them. The default mutation rate landscape in mammalian genomes results in active genes having low mutation rates because of a combination of factors that increase DNA repair: early DNA replication, transcription, active chromatin modifications and accessible chromatin. Therefore, either an increase in the global mutation rate or a redistribution of mutations from inactive to active DNA can increase the rate at which consequential mutations are acquired in active genes. Several environmental carcinogens and intrinsic mechanisms operating in tumor cells likely cause cancer by this second mechanism: by specifically increasing the mutation rate in active regions of the genome.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The impact of rare germline variants on human somatic mutation processes

  • Vali-Pour, Mischan
  • Lehner, Ben, 1978-
  • Supek, Fran
Somatic mutations are an inevitable component of ageing and the most important cause of cancer. The rates and types of somatic mutation vary across individuals, but relatively few inherited influences on mutation processes are known. We perform a gene-based rare variant association study with diverse mutational processes, using human cancer genomes from over 11,000 individuals of European ancestry. By combining burden and variance tests, we identify 207 associations involving 15 somatic mutational phenotypes and 42 genes that replicated in an independent data set at a false discovery rate of 1%. We associate rare inherited deleterious variants in genes such as MSH3, EXO1, SETD2, and MTOR with two phenotypically different forms of DNA mismatch repair deficiency, and variants in genes such as EXO1, PAXIP1, RIF1, and WRN with deficiency in homologous recombination repair. In addition, we identify associations with other mutational processes, such as APEX1 with APOBEC-signature mutagenesis. Many of the genes interact with each other and with known mutator genes within cellular sub-networks. Considered collectively, damaging variants in the identified genes are prevalent in the population. We suggest that rare germline variation in diverse genes commonly impacts mutational processes in somatic cells., M.V.P. was supported by a Spanish Ministry of Science and Innovation FPI Fellowship (ref.: PRE2018-084410). Work in the lab of B.L. is funded by European Research Council (ERC) Advanced (883742) and Consolidator (616434) grants, the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Centre of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322), and the CERCA Program/Generalitat de Catalunya. Work in the lab of F.S. is funded by the ERC Starting Grant HYPER-INSIGHT (757700), the Horizon2020 RIA grant DECIDER (965193), Spanish Ministry of Science and Innovation grant REPAIRSCAPE (PID2020-118795GB-I00), the EMBO YIP program, the Severo Ochoa Centre of Excellence award to IRB Barcelona, and the CERCA Program/Generalitat de Catalunya. We thank Solip Park for method consultations, comments, and discussions.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition

  • Rodríguez Martín, Bernardo
  • PCAWG Structural Variation Working Group
  • PCAWG Consortium
  • Ossowski, Stephan
About half of all cancers have somatic integrations of retrotransposons. Here, to characterize their role in oncogenesis, we analyzed the patterns and mechanisms of somatic retrotransposition in 2,954 cancer genomes from 38 histological cancer subtypes within the framework of the Pan-Cancer Analysis of Whole Genomes (PCAWG) project. We identified 19,166 somatically acquired retrotransposition events, which affected 35% of samples and spanned a range of event types. Long interspersed nuclear element (LINE-1; L1 hereafter) insertions emerged as the first most frequent type of somatic structural variation in esophageal adenocarcinoma, and the second most frequent in head-and-neck and colorectal cancers. Aberrant L1 integrations can delete megabase-scale regions of a chromosome, which sometimes leads to the removal of tumor-suppressor genes, and can induce complex translocations and large-scale duplications. Somatic retrotranspositions can also initiate breakage-fusion-bridge cycles, leading to high-level amplification of oncogenes. These observations illuminate a relevant role of L1 retrotransposition in remodeling the cancer genome, with potential implications for the development of human tumors., J.M.C.T. is supported by European Research Council (ERC) Starting Grant 716290 ‘SCUBA CANCERS’, Ramon y Cajal grant RYC-2014-14999 and Spanish Ministry of Economy, Industry and Competitiveness (MINECO) grant SAF2015-66368-P. B.R.-M., E.G.A., M.S.G. and S.Z. are supported by PhD fellowships from Xunta de Galicia (Spain) ED481A-2016/151, ED481A-2017/299, ED481A-2017/306 and ED481A-2018/199, respectively. F.S. was supported by ERC Starting Grant 757700 ‘HYPER-INSIGHT’, MINECO grant BFU2017-89833-P ‘RegioMut’, and further acknowledges institutional funding from the MINECO Severo Ochoa award and from the CERCA Programme of the Catalan Government. Y.S.J. was supported by Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI16C2387). A.L.B. is supported by MINECO PhD fellowship BES-2016-078166. M.T. was supported by MINECO grant SAF2015-73916-JIN. R.B. received funding through the National Institutes of Health (U24CA210978 and R01CA188228). M.G.B. received funding through MINECO, AEI, Xunta de Galicia and FEDER (BFU2013-41554-P, BFU2016-78121-P, ED431F 2016/019). N.B. is supported by a My First AIRC grant from the Associazione Italiana Ricerca sul Cancro (number 17658). J.D. is a postdoctoral fellow of the Research Foundation Flanders (FWO) and the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant agreement number 703594-DECODE). K.C. and Z.C. are supported by NIH R01 CA172652 and U41 HG007497. Z.C. is supported by an American Heart Association Institutional Data Fellowship Award (17IF33890015). P.A.W.E. is supported by Cancer Research UK. E.A.L. is supported by K01AG051791. I.M. is supported by Cancer Research UK (C57387/A21777). S.M.W. received funding through a SNSF Early Postdoc Mobility fellowship (P2ELP3_155365) and an EMBO Long-Term Fellowship (ALTF 755-2014). J.W. received funding from the Danish Medical Research Council (DFF-4183-00233). J.O.K. is supported by an ERC Starting Grant. This work is supported by The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001202), the UK Medical Research Council (FC001202) and the Wellcome Trust (FC001202). H.H.K. is supported by grants from the National Institute of General Medical Sciences (P50GM107632 and 1R01GM099875). K.H.B. is supported by P50GM107632, R01CA163705 and R01GM124531. This work was supported by the TransTumVar project PN013600.. This work was supported by the Wellcome Trust grant 09805
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The impact of rare germline variants on human somatic mutation processes

  • Vali-Pour, Mischan
  • Solip, Park
  • Espinosa-Carrasco, José
  • Ortiz-Martínez, Daniel
  • Lehner, Ben, 1978-
  • Supek, Fran
Somatic mutations are an inevitable component of ageing and the most important cause of cancer. The rates and types of somatic mutation vary across individuals, but relatively few inherited influences on mutation processes are known. We perform a gene-based rare variant association study with diverse mutational processes, using human cancer genomes from over 11,000 individuals of European ancestry. By combining burden and variance tests, we identify 207 associations involving 15 somatic mutational phenotypes and 42 genes that replicated in an independent data set at a false discovery rate of 1%. We associate rare inherited deleterious variants in genes such as MSH3, EXO1, SETD2, and MTOR with two phenotypically different forms of DNA mismatch repair deficiency, and variants in genes such as EXO1, PAXIP1, RIF1, and WRN with deficiency in homologous recombination repair. In addition, we identify associations with other mutational processes, such as APEX1 with APOBEC-signature mutagenesis. Many of the genes interact with each other and with known mutator genes within cellular sub-networks. Considered collectively, damaging variants in the identified genes are prevalent in the population. We suggest that rare germline variation in diverse genes commonly impacts mutational processes in somatic cells., M.V.P. was supported by a Spanish Ministry of Science and Innovation FPI Fellowship (ref.: PRE2018-084410). Work in the lab of B.L. is funded by European Research Council (ERC) Advanced (883742) and Consolidator (616434) grants, the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Centre of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322), and the CERCA Program/Generalitat de Catalunya. Work in the lab of F.S. is funded by the ERC Starting Grant HYPER-INSIGHT (757700), the Horizon2020 RIA grant DECIDER (965193), Spanish Ministry of Science and Innovation grant REPAIRSCAPE (PID2020-118795GB-I00), the EMBO YIP program, the Severo Ochoa Centre of Excellence award to IRB Barcelona, and the CERCA Program/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules

  • Toledano, Ignasi
  • Supek, Fran
  • Lehner, Ben
Premature termination codons (PTCs) cause ~10-20% of inherited diseases and are a major mechanism of tumor suppressor gene inactivation in cancer. A general strategy to alleviate the effects of PTCs would be to promote translational readthrough. Nonsense suppression by small molecules has proven effective in diverse disease models, but translation into the clinic is hampered by ineffective readthrough of many PTCs. Here we directly tackle the challenge of defining drug efficacy by quantifying the readthrough of ~5,800 human pathogenic stop codons by eight drugs. We find that different drugs promote the readthrough of complementary subsets of PTCs defined by local sequence context. This allows us to build interpretable models that accurately predict drug-induced readthrough genome-wide, and we validate these models by quantifying endogenous stop codon readthrough. Accurate readthrough quantification and prediction will empower clinical trial design and the development of personalized nonsense suppression therapies., Work in the Supek laboratory was supported by an ERC StG ‘HYPER-INSIGHT’ (757700) and ERC CoG ‘STRUCTOMATIC’ (101088342), Horizon2020 project ‘DECIDER’ (965193), Horizon Europe project ‘LUCIA’ (101096473), Spanish government project ‘REPAIRSCAPE’, CaixaResearch project ‘POTENT-IMMUNO’ (HR22-00402), an ICREA professorship to F.S., the SGR funding from the Catalan government and a Novo Nordisk Fonden starting package. Work in the Lehner laboratory was funded by European Research Council (ERC) Advanced (grant 883742) and Consolidator (grant 616434), the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Center of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322) and the CERCA Program/Generalitat de Catalunya. The authors would like to thank the four members E. Ramírez, A. Bote, E. Julià and Ò. Fornàs of the Flow Cytometry CRG Core Unit for their support and time, together with G. Palou (IRB) for his help in retrieving the transcript sequences from the Ensembl database and all members of the Supek and Lehner laboratories for helpful discussions and suggestions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mutational signatures are markers of drug sensitivity of cancer cells

  • Levatić, Jurica
  • Salvadores, Marina|||0000-0002-7850-7691
  • Fuster-Tormo, Francisco|||0000-0002-1220-6183
  • Supek, Fran
Genomic analyses have revealed mutational footprints associated with DNA maintenance gone awry, or with mutagen exposures. Because cancer therapeutics often target DNA synthesis or repair, we asked if mutational signatures make useful markers of drug sensitivity. We detect mutational signatures in cancer cell line exomes (where matched healthy tissues are not available) by adjusting for the confounding germline mutation spectra across ancestries. We identify robust associations between various mutational signatures and drug activity across cancer cell lines; these are as numerous as associations with established genetic markers such as driver gene alterations. Signatures of prior exposures to DNA damaging agents - including chemotherapy - tend to associate with drug resistance, while signatures of deficiencies in DNA repair tend to predict sensitivity towards particular therapeutics. Replication analyses across independent drug and CRISPR genetic screening data sets reveal hundreds of robust associations, which are provided as a resource for drug repurposing guided by mutational signature markers.